BioReference Laboratories, Inc. (NASDAQ:BRLI) will release its fourth quarter earnings for 2009 on Thursday, December 17. The company has scheduled a conference call for 10:30 am ET that morning to review the financial results. Hosting the call will be BioReference President and Chief Executive Officer Marc Grodman M.D. The conference call will be accessible via webcast on the company’s website, http://www.bioreference.com/. The webcast will be archived on the site for instant replay for thirty days following the end of the event.
Penny Stock Professor, a leading financial publication, is pleased to alert investors of stocks on the move. Sign Up for our Free Penny Stock Picks.
Bio-Reference Laboratories, Inc. (Bio-Reference) is principally engaged in providing clinical laboratory testing services, primarily to customers in the greater New York metropolitan area, as well as to customers in a number of other states. Bio-Reference offers a list of chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radioimmuno analysis, toxicology (including drug screening), pap smears, tissue pathology (biopsies) and other tissue analysis. The Company operates two clinical laboratories, one in Elmwood Park, New Jersey and one in Valley Cottage, New York, and an andrology laboratory in New York City, a cytogenetics testing laboratory located in Milford, Massachusetts, a pathology laboratory in Poughkeepsie, New York, a pathology laboratory in Clarksburg, Maryland and a genetics laboratory in Gaithersburg, Maryland.
Follow us on Twitter: http://www.twitter.com/pennystockspro
Sign up for the free Penny Stock Professor newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
About Us
Penny Stock Professor is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
